| Property | Value |
|---|
|
?:abstract
|
-
BACKGROUND: Coagulopathy has emerged as a hallmark issue of the coronavirus 2019 (COVID-19) Medical facilities are faced with the challenge of developing institutional thromboprophylaxis protocols;however, due to the novelty of the disease, there is a dearth of high-quality, prospective evidence for decision making OBSERVATIONS: The US National Institutes of Health along with 4 leading societies in the fields of thrombosis and hemostasis have published guidance based on expert consensus that helps provide a framework for local policy development While there is agreement in a few areas, there are notable and sometimes considerable differences in recommendations that facilities should discuss when developing local guidance CONCLUSIONS: This document aims to streamline and simplify the available guidance so health care providers can readily identify consensus and divergence of COVID-19 thromboprophylaxis recommendations Additionally, the authors provide and briefly highlight the COVID-19 thromboprophylaxis protocol of the US Department of Veterans Affairs Tennessee Valley Healthcare System in Nashville and Murfreesboro to serve as an example of a guideline-directed approach for order-set development
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:source
|
|
|
?:title
|
-
COVID-19 and Venous Thromboembolism Pharmacologic Thromboprophylaxis
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}